SAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F ...
Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results